Ohio State University

Tenure-Track Faculty in Immuno-Oncology

Pelotonia Institute for Immuno-Oncology

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) is seeking candidates for tenure-track faculty positions to work in the Pelotonia Institute for Immuno-Oncology (PIIO) in the following research areas:

  • Cancer Immuno-Genomics: a program conducted in partnership with Nationwide Children’s Hospital which involves understanding the relationship between cancer genomics and immune evasion and includes epigenetics, neo-antigen vaccine, epitope prediction, TCR repertoire analysis, HLA typing, and CRISPR screening;
  • Cell Therapy: where immune cells are collected from a patient’s blood, engineered, and returned to that patient to target and eradicate cancer and includes adoptive cell therapy with T cells and natural killer cells;
  • Systems Immuno-Oncology: which seeks a better understanding of cellular systems to create more efficient and effective immunological tools to fight cancer and includes immune regulation, microbiome, NK and T cell biology, and tumor microenvironment;
  • Translational Immuno-Oncology: an area that focuses on transforming immuno-oncology discoveries into new or improved cancer treatments applicable at patient bedsides. This team works with the Drug Development Institute at the OSUCCC – James on developing new drug therapies;
  • Immuno-Informatics (Data Science) Group: where big data and quantitative science are used to improve immuno-oncology research and includes machine learning, neo-antigen discovery, spatial statistics, etc;
  • Immune Monitoring and Discovery: which is backed by a new facility with technology that allows scientists to get a 360-degree view—down to the single-cell level—of what happens in the immune system during treatment with immuno-oncology agents.

The Pelotonia Institute for Immuno-Oncology (PIIO) is a comprehensive bench-to-bedside research initiative focused on developing life-saving cancer immunotherapy breakthroughs at all levels – from prevention to treatment to survivorship. Established by a pledge of more than $100 million from Pelotonia (pelotonia.org) and the OSUCCC - James, the PIIO represents Ohio State University's commitment to grow the exciting area of immuno-oncology (cancer.osu.edu/PIIO). The Institute’s initiatives include recruiting outstanding researchers; developing first-in-class, first-in-man IO agents; training the next generation of IO scientists; and fostering high-impact and holistic partnerships.

Candidates will have access to state-of-the-art laboratory spaces; cutting-edge core research facilities (Spectrum Flow Cytometry, Time-of-Flight Mass Cytometry, Multiplex Histology, Single Cell Technology, GMP Facility for Cell Therapy, Antibody Engineering Facility, Immuno-Informatics and more); a competitive salary commensurate with experience, and ample start-up funding.

Applicants must hold advanced degrees such as a MD, DVM, PharmD, PhD, or MD/PhD. The successful candidate is expected to maintain an extramurally funded research program, perform collaborative research with others, participate in graduate and medical education, and must be board-certified and meet medical licensure requirements in Ohio for those also pursuing a clinical position.

The Ohio State University is an EOE/AA/M/F/D/V employer.

Send cover letter, Curriculum Vitae, 2-3 page description of current and future research interests, and contact information for three references to the office of the director of the PIIO, Zihai Li, MD, PhD, via Tamra Brooks at tamra.brooks@osumc.edu.

Applications will be accepted until the positions are filled.

Job Classifications
Job Category
Institution

Editors Note

MinorityPostdoc.org publishes postdoctoral & professional job / opportunity advertisements. When participating in these opportunities, please mention that you saw the ad here. Advertisers can request information on rates and terms by contacting us at info@MinorityPostdoc.org

Last updated: 2020-11-13